Senores Pharmaceuticals Ltd is a growing pharmaceutical company focused on developing and delivering high-quality generic medicines and specialized formulations. Known for its innovation and customer-centric approach, the company caters to both domestic and international markets, with a strong presence in regulated and emerging regions. Senores Pharmaceuticals emphasizes research and development to bring affordable and effective solutions across therapeutic areas. Senores Pharmaceuticals Share Price on NSE as of 6 January 2025 is 554.50 INR. Here will provide you more details on Senores Pharmaceuticals Share Price Target 2025, 2026 to 2030.
Senores Pharmaceuticals Ltd: Market Overview
- Open: ₹576.35
- High: ₹576.35
- Low: ₹536.70
- Previous Close: ₹573.15
- Volume: 1,227,042
- Value (Lacs): ₹6,773.27
- VWAP: ₹554.05
- UC Limit: ₹687.75
- LC Limit: ₹458.55
- 52 Week High: ₹609.65
- 52 Week Low: ₹536.70
- Mkt Cap (Rs. Cr.): ₹2,542
- Face Value: ₹10
Senores Pharmaceuticals Ltd Competitors
Senores Pharmaceuticals Ltd operates in the competitive pharmaceutical industry alongside several notable companies. Here are four competitors with their respective market capitalizations:
- Blue Jet Healthcare Ltd: Specializes in niche pharmaceutical products with a market capitalization of approximately ₹10,410 crore.
- Gujarat Themis Biosyn Ltd: Focuses on the production of active pharmaceutical ingredients (APIs) and has a market capitalization of around ₹1,000 crore.
- Indoco Remedies Ltd: Engages in the development and manufacture of pharmaceutical formulations and active pharmaceutical ingredients, with a market capitalization of approximately ₹2,500 crore.
-
Solara Active Pharma Sciences Ltd: Specializes in manufacturing APIs and has a market capitalization of about ₹1,800 crore.
Senores Pharmaceuticals Share Price Chart
Senores Pharmaceuticals Share Price Target Tomorrow 2025 To 2030
| Senores Pharmaceuticals Share Price Target Years | Share Price Target |
| 2025 | ₹610 |
| 2026 | ₹710 |
| 2027 | ₹809 |
| 2028 | ₹908 |
| 2029 | ₹1010 |
| 2030 | ₹1120 |
Senores Pharmaceuticals Share Price Target 2025
Senores Pharmaceuticals share price target 2025 Expected target could be ₹610. Here are 4 Key Factors Affecting Growth for “Senores Pharmaceuticals Share Price Target 2025”:
- Expansion in Niche Markets: Senores Pharmaceuticals’ focus on niche pharmaceutical segments like specialized formulations and APIs can drive revenue growth and differentiate it from competitors in the crowded pharmaceutical industry.
- Regulatory Approvals: Securing approvals from global regulatory bodies such as the US FDA and EU authorities for new products or facilities can enhance market presence and support share price growth.
- Innovation and R&D: Investment in research and development to launch new products or improve existing formulations will be a critical driver of growth, fostering competitiveness in both domestic and international markets.
-
Strategic Partnerships and Exports: Collaborations with international firms and an increased focus on export opportunities in emerging and developed markets can boost revenue streams and market reach.
Senores Pharmaceuticals Share Price Target 2030
Senores Pharmaceuticals share price target 2030 Expected target could be ₹1120. Here are 4 Risks and Challenges for “Senores Pharmaceuticals Share Price Target 2030”:
- Regulatory Hurdles: Compliance with stringent international and domestic regulations may pose challenges. Any delay or denial of approvals could impact product launches and revenue.
- Rising Competition: Intense competition from established pharmaceutical giants and emerging players in niche markets could pressure margins and limit market share growth.
- Supply Chain Disruptions: Dependence on raw material imports, especially active pharmaceutical ingredients (APIs), exposes the company to supply chain risks, cost fluctuations, and geopolitical tensions.
-
Intellectual Property and Litigation Risks: Patent expirations, intellectual property disputes, or legal challenges could hinder the company’s ability to sustain exclusive products and impact profitability.
Senores Pharmaceuticals Ltd Shareholding Pattern
- Promoters: 45.76%
- FII: 5.51%
- DII: 14.98%
- Public: 33.75%
Senores Pharmaceuticals Ltd Financials
| (INR) | 2024 | Y/Y change |
| Revenue | 2.15B | 507.08% |
| Operating expense | 740.63M | 535.90% |
| Net income | 314.55M | 273.00% |
| Net profit margin | 14.66 | -38.56% |
| Earnings per share | — | — |
| EBITDA | 379.72M | 246.62% |
| Effective tax rate | -31.13% | — |
Read Also:- Shraddha Prime Share Price Target Tomorrow 2025 To 2030- Prediction, Market Overview
